<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071798</url>
  </required_header>
  <id_info>
    <org_study_id>ML22639</org_study_id>
    <nct_id>NCT01071798</nct_id>
  </id_info>
  <brief_title>An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis</brief_title>
  <official_title>A Prospective, Multi-center, Non-interventional Observational Study to Evaluate the Safety and Effectiveness of MabThera® (Rituximab) Within the First 6 Months (in Case of Re-therapy the First 12 Months) of Treatment in Patients With Severe Active Rheumatoid Arthritis in Routine Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This prospective observational study aims to evaluate safety, application and onset of effect
      of rituximab in clinical routine treatment of severe active rheumatoid arthritis during the
      first 6 months (in case of re-therapy: 12 months).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DAS28 Score</measure>
    <time_frame>at baseline of each cycle and approximately 15 days, 6 weeks (only cycle 1), 12 weeks (3 months), 18 weeks (only cycle 1), and 24 weeks (6 months) after the start of the respective cycle</time_frame>
    <description>The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-rated rheumatoid arthritis [RA] activity assessment) with transformed scores ranging 0 to 10; higher scores indicate greater affectation due to disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HAQ Disability Index (HAQ-DI)</measure>
    <time_frame>at baseline of each cycle and approximately 15 days, 6 weeks (only cycle 1), 12 weeks (3 months), 18 weeks (only cycle 1), and 24 weeks (6 months) after the start of the respective cycle</time_frame>
    <description>The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific subcategory items. The standard disability score is calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>during Cycle 1, during Cycle 2, during the trial (within 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received Only One Treatment Cycle With Clinically Relevant Changes in HAQ-Score at Last Visit During Therapy Compared to Baseline (Categorized)</measure>
    <time_frame>24 weeks after starting Cycle 1</time_frame>
    <description>In the Main Analysis Set participants with only one treatment cycle, the HAQ score was categorized for 12 subgroups as Clinically relevant improvement of HAQ-Score ≥0.3, Other or no clinical relevant change of HAQ Score, or Clinically relevant worsening of HAQ Score ≥0.3. Subgroups are defined as Anti-Cyclic citrullinated peptide (CCP) and Rheumatoid factor (RF) negative (-), positive (+), or Non-specified (n.sp.) and Seropositive Non-specified (n.sp.), Seronegative, or Seropositive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received Two Cycles With Clinically Relevant Changes in HAQ-Score at Last Visit During Therapy Compared to Baseline (Categorized)</measure>
    <time_frame>24 weeks after starting Cycle 2</time_frame>
    <description>In the Subpopulation With Two Cycles, the HAQ score was categorized for 12 subgroups as Clinically relevant improvement of HAQ-Score ≥0.3, Other or no clinical relevant change of HAQ Score, or Clinically relevant worsening of HAQ Score ≥0.3. Subgroups are defined as Anti-Cyclic citrullinated peptide (CCP) and Rheumatoid factor (RF) negative (-), positive (+), or Non-specified (n.sp.) and Seropositive Non-specified (n.sp.), Seronegative, or Seropositive.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1653</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Main Analysis Set</arm_group_label>
    <description>Participants who received at least one cycle of rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>As prescribed by physician</description>
    <arm_group_label>Main Analysis Set</arm_group_label>
    <other_name>Mabthera</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants starting treatment with rituximab
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No pretreatment with rituximab

          -  Age 18 years or older

          -  Patients with active, severe rheumatoid arthritis with prescription of rituximab
             according to German Summary of Product Characteristics (SmPC - &quot;Fachinformation&quot;)

          -  Patients with signed informed consent

          -  Female patients with secure contraception

        Exclusion Criteria:

          -  Violation of Selection criteria:

               1. Active severe infection

               2. Severe heart failure (NYHA class IV) or severe, uncontrollable heart disease

               3. Participation in an interventional study within the last 3 months before therapy
                  start with rituximab

               4. Pretreatment with rituximab

               5. Age &lt;18 years

               6. Known intolerability of monoclonal antibodies or chimeric monoclonal antibodies

               7. Known pregnancy or breastfeeding

          -  Data of patients without approval of data by the physician

          -  Patients without informed consent

          -  Double documentation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Tony HP, Roll P, Mei HE, Blümner E, Straka A, Gnuegge L, Dörner T; FIRST/ ReFIRST study teams. Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol. 2015 Nov-Dec;33(6):887-94. Epub 2015 Oct 30.</citation>
    <PMID>26517829</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <results_first_submitted>November 12, 2015</results_first_submitted>
  <results_first_submitted_qc>January 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2016</results_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Data were recorded throughout Germany in 264 study centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Main Analysis Set</title>
          <description>Participants who received at least one cycle of rituximab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Participants Who Received One Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1653"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Baseline and Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="1653"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1588"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of tolerability</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient requirement</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change of therapy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe concomitant disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Subpopulation Who Received Two Cycles</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="820"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Baseline and Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="820"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="805"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Remission</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Tolerability</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Requirement</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Main analysis population</population>
      <group_list>
        <group group_id="B1">
          <title>Main Analysis Set</title>
          <description>Participants who received at least one cycle of rituximab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1653"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" lower_limit="52.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>DAS28 Score</title>
        <description>The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-rated rheumatoid arthritis [RA] activity assessment) with transformed scores ranging 0 to 10; higher scores indicate greater affectation due to disease activity.</description>
        <time_frame>at baseline of each cycle and approximately 15 days, 6 weeks (only cycle 1), 12 weeks (3 months), 18 weeks (only cycle 1), and 24 weeks (6 months) after the start of the respective cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Main Analysis Set</title>
            <description>Participants who received at least one cycle of rituximab</description>
          </group>
          <group group_id="O2">
            <title>Seronegative Participants</title>
            <description>Subgroup of seronegative participants</description>
          </group>
          <group group_id="O3">
            <title>Seropositive Participants</title>
            <description>Subgroup of seropositive participants</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28 Score</title>
          <description>The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-rated rheumatoid arthritis [RA] activity assessment) with transformed scores ranging 0 to 10; higher scores indicate greater affectation due to disease activity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1653"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="1186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=1396,150,1186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="1.4"/>
                    <measurement group_id="O2" value="5.0" spread="1.4"/>
                    <measurement group_id="O3" value="5.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 days (n=1133,120,957)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.4"/>
                    <measurement group_id="O2" value="4.6" spread="1.4"/>
                    <measurement group_id="O3" value="4.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks (n=778,73,670)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.4"/>
                    <measurement group_id="O2" value="4.3" spread="1.4"/>
                    <measurement group_id="O3" value="4.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks (n=785,75,666)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.3"/>
                    <measurement group_id="O2" value="4.0" spread="1.3"/>
                    <measurement group_id="O3" value="4.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 weeks (n=601,57,520)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.3"/>
                    <measurement group_id="O2" value="4.1" spread="1.4"/>
                    <measurement group_id="O3" value="3.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks (n=641,60,553)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.4"/>
                    <measurement group_id="O2" value="4.1" spread="1.3"/>
                    <measurement group_id="O3" value="3.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start 2nd cycle (n=588,47,517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.4"/>
                    <measurement group_id="O2" value="4.2" spread="1.5"/>
                    <measurement group_id="O3" value="4.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 days (n=525,43,460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.4"/>
                    <measurement group_id="O2" value="4.0" spread="1.5"/>
                    <measurement group_id="O3" value="3.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=451,37,393)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.3"/>
                    <measurement group_id="O2" value="3.7" spread="1.5"/>
                    <measurement group_id="O3" value="3.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=491,34,438)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.4"/>
                    <measurement group_id="O2" value="3.9" spread="1.6"/>
                    <measurement group_id="O3" value="3.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HAQ Disability Index (HAQ-DI)</title>
        <description>The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific subcategory items. The standard disability score is calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).</description>
        <time_frame>at baseline of each cycle and approximately 15 days, 6 weeks (only cycle 1), 12 weeks (3 months), 18 weeks (only cycle 1), and 24 weeks (6 months) after the start of the respective cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Main Analysis Set</title>
            <description>Participants who received at least one cycle of rituximab</description>
          </group>
          <group group_id="O2">
            <title>Seronegative Participants</title>
            <description>Subgroup of seronegative participants</description>
          </group>
          <group group_id="O3">
            <title>Seropositive Participants</title>
            <description>Subgroup of seropositive participants</description>
          </group>
        </group_list>
        <measure>
          <title>HAQ Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific subcategory items. The standard disability score is calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1653"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="1326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=1579,174,1326)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.7"/>
                    <measurement group_id="O2" value="1.5" spread="0.7"/>
                    <measurement group_id="O3" value="1.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 days (n=1514,169,1270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.7"/>
                    <measurement group_id="O2" value="1.4" spread="0.8"/>
                    <measurement group_id="O3" value="1.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks (n=983,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.7"/>
                    <measurement group_id="O2" value="NA">These data were not collected</measurement>
                    <measurement group_id="O3" value="NA">These data were not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks (n=1015,116,848)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="1.3" spread="0.8"/>
                    <measurement group_id="O3" value="1.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 weeks (n=784,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="NA">These data were not collected</measurement>
                    <measurement group_id="O3" value="NA">These data were not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks (n=810,90,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="1.3" spread="0.8"/>
                    <measurement group_id="O3" value="1.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start 2nd cycle (n=768,68,669)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="1.4" spread="0.8"/>
                    <measurement group_id="O3" value="1.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 days (n=706,67,610)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="1.2" spread="0.7"/>
                    <measurement group_id="O3" value="1.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=594,59,508)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.7"/>
                    <measurement group_id="O2" value="1.3" spread="0.7"/>
                    <measurement group_id="O3" value="1.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=626,56,546)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="1.3" spread="0.8"/>
                    <measurement group_id="O3" value="1.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Treatment-Emergent Adverse Event (TEAE)</title>
        <time_frame>during Cycle 1, during Cycle 2, during the trial (within 12 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1</title>
            <description>During Cycle 1 - Main Analysis Set</description>
          </group>
          <group group_id="O2">
            <title>Cycle 2</title>
            <description>During Cycle 2 - Subpopulation With Two Cycles</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>During the Trial - All Participants</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Treatment-Emergent Adverse Event (TEAE)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1653"/>
                <count group_id="O2" value="820"/>
                <count group_id="O3" value="1653"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                    <measurement group_id="O2" value="21.1"/>
                    <measurement group_id="O3" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="5.7"/>
                    <measurement group_id="O3" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="6.2"/>
                    <measurement group_id="O3" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any related serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received Only One Treatment Cycle With Clinically Relevant Changes in HAQ-Score at Last Visit During Therapy Compared to Baseline (Categorized)</title>
        <description>In the Main Analysis Set participants with only one treatment cycle, the HAQ score was categorized for 12 subgroups as Clinically relevant improvement of HAQ-Score ≥0.3, Other or no clinical relevant change of HAQ Score, or Clinically relevant worsening of HAQ Score ≥0.3. Subgroups are defined as Anti-Cyclic citrullinated peptide (CCP) and Rheumatoid factor (RF) negative (-), positive (+), or Non-specified (n.sp.) and Seropositive Non-specified (n.sp.), Seronegative, or Seropositive.</description>
        <time_frame>24 weeks after starting Cycle 1</time_frame>
        <population>Main Analysis Set with HAQ Score</population>
        <group_list>
          <group group_id="O1">
            <title>Improved</title>
            <description>Clinically relevant improvement of HAQ-Score ≥0.3</description>
          </group>
          <group group_id="O2">
            <title>No Change</title>
            <description>Other or no clinical relevant change of HAQ-Score</description>
          </group>
          <group group_id="O3">
            <title>Worse</title>
            <description>Clinically relevant worsening of HAQ Score ≥0.3</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Only One Treatment Cycle With Clinically Relevant Changes in HAQ-Score at Last Visit During Therapy Compared to Baseline (Categorized)</title>
          <description>In the Main Analysis Set participants with only one treatment cycle, the HAQ score was categorized for 12 subgroups as Clinically relevant improvement of HAQ-Score ≥0.3, Other or no clinical relevant change of HAQ Score, or Clinically relevant worsening of HAQ Score ≥0.3. Subgroups are defined as Anti-Cyclic citrullinated peptide (CCP) and Rheumatoid factor (RF) negative (-), positive (+), or Non-specified (n.sp.) and Seropositive Non-specified (n.sp.), Seronegative, or Seropositive.</description>
          <population>Main Analysis Set with HAQ Score</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="366"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subgroup 1: Anti-CCP-/RF- (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 2: Anti-CCP-/RF+ (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 3: Anti-CCP+/RF- (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 4: Anti-CCP+/RF+ (n=375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="185"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 5: Anti-CCP n.sp./RF+ (n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 6: Anti-CCP n.sp./RF- (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 7: Anti-CCP+/RF n.sp. (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 8: Anti-CCP-/RF n.sp. (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 9: Seropositive n.sp. (n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 10: Anti-CCP and RF n.sp. (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 1+6+8: seronegative (n=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 2+3+4+5+7+9: seropositive (n=584)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="304"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received Two Cycles With Clinically Relevant Changes in HAQ-Score at Last Visit During Therapy Compared to Baseline (Categorized)</title>
        <description>In the Subpopulation With Two Cycles, the HAQ score was categorized for 12 subgroups as Clinically relevant improvement of HAQ-Score ≥0.3, Other or no clinical relevant change of HAQ Score, or Clinically relevant worsening of HAQ Score ≥0.3. Subgroups are defined as Anti-Cyclic citrullinated peptide (CCP) and Rheumatoid factor (RF) negative (-), positive (+), or Non-specified (n.sp.) and Seropositive Non-specified (n.sp.), Seronegative, or Seropositive.</description>
        <time_frame>24 weeks after starting Cycle 2</time_frame>
        <population>Subpopulation With Two Cycles with HAQ Score</population>
        <group_list>
          <group group_id="O1">
            <title>Improved</title>
            <description>Clinically relevant improvement of HAQ-Score ≥0.3</description>
          </group>
          <group group_id="O2">
            <title>No Change</title>
            <description>Other or no clinical relevant change of HAQ-Score</description>
          </group>
          <group group_id="O3">
            <title>Worse</title>
            <description>Clinically relevant worsening of HAQ Score ≥0.3</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Two Cycles With Clinically Relevant Changes in HAQ-Score at Last Visit During Therapy Compared to Baseline (Categorized)</title>
          <description>In the Subpopulation With Two Cycles, the HAQ score was categorized for 12 subgroups as Clinically relevant improvement of HAQ-Score ≥0.3, Other or no clinical relevant change of HAQ Score, or Clinically relevant worsening of HAQ Score ≥0.3. Subgroups are defined as Anti-Cyclic citrullinated peptide (CCP) and Rheumatoid factor (RF) negative (-), positive (+), or Non-specified (n.sp.) and Seropositive Non-specified (n.sp.), Seronegative, or Seropositive.</description>
          <population>Subpopulation With Two Cycles with HAQ Score</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subgroup 1: Anti-CCP-/RF- (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 2: Anti-CCP-/RF+ (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 3: Anti-CCP+/RF- (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 4: Anti-CCP+/RF+ (n=314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 5: Anti-CCP n.sp./RF+ (n=100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 6: Anti-CCP n.sp./RF- (n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 7: Anti-CCP+/RF n.sp. (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 8: Anti-CCP-/RF n.sp. (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 9: Seropositive n.sp. (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 10: Anti-CCP and RF n.sp. (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 1+6+8: seronegative (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup 2+3+4+5+7+9: seropositive (n=485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="205"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years, 6 months</time_frame>
      <desc>AEs which cannot be assigned to a Cycle due to missing/incomplete start date are counted in the Total column only</desc>
      <group_list>
        <group group_id="E1">
          <title>Cycle 1</title>
          <description>During Cycle 1 - Main Analysis Set</description>
        </group>
        <group group_id="E2">
          <title>Cycle 2</title>
          <description>During Cycle 2 - Subpopulation With Two Cycles</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>During the entire trial</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="180" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Drug effect decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Gallbladder cholesterolosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Acute endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cranial nerve infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Encephalitis brain stem</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pneumococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Biopsy prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Prostatic acid phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Musculoskeletal deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cystitis glandularis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pleural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arterial repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Elbow operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Nasal septal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Tendon operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Tendon sheath incision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1653"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1653"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>1-800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

